parg inhibitor ide161
parg inhibitor ide161: sourced relationships with 1 company · 2 clinical trials tracked.
parg inhibitor ide161 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could parg inhibitor ide161 → IDYA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | Phase 2/Phase 3 |
Clinical Trial Registry Records (2)
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer
Primary endpoint: Part 1A: Safety and Tolerability of IDE849 (Monotherapy)
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Primary endpoint: Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE
Frequently asked questions
Which companies have sourced relationships with parg inhibitor ide161?
parg inhibitor ide161 has dated SEC/FDA relationship records for IDEAYA Biosciences, Inc..
How many clinical trials involve parg inhibitor ide161?
BioSniper tracks 2 clinical trials involving parg inhibitor ide161.